Compounds > 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline
Page last updated: 2024-09-03

1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline and Atherosclerotic Parkinsonism

1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline has been researched along with Atherosclerotic Parkinsonism in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bringmann, G; God, R; Heim, C; Rausch, WD; Reichmann, H; Riederer, P; Sontag, KH; Sontag, TA; Wesemann, W1

Other Studies

1 other study(ies) available for 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline and Atherosclerotic Parkinsonism

ArticleYear
Long-term behavioural effects of TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) after subchronic treatment in rats.
    Journal of neural transmission. Supplementum, 1995, Volume: 46

    Topics: Analysis of Variance; Animals; Apomorphine; Carbolines; Drug Administration Schedule; Female; Motor Activity; Neurotoxins; Parkinson Disease, Secondary; Rats; Rats, Wistar; Time Factors

1995